Hey there,
In biotech, the real money is made when a company solves a problem others couldn't.
For years, the CD47 cancer pathway has been the holy grail. Block it, and you can make today's top immunotherapies work better. Fail, and you risk dangerous side effects.
This team claims they've cracked it with a drug that homes in on tumors and immune cells, leaving healthy red blood cells and platelets alone.
If they're right, it could unlock a new wave of combination therapies, partnerships, and licensing deals.
But what makes this even more interesting is their funding play: a potential $500 million investment arm, separate from the biotech itself, to finance operations without the dilution that usually crushes early investors.
Two billion-dollar markets. Multiple near-term catalysts. A history of moving sharply on news.
It's the kind of rare setup that doesn't linger unnoticed for long.
See why the clock may already be ticking.
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
This message is a PAID ADVERTISEMENT for Liminatus Pharma Inc (NASDAQ:LIMN) from Market Jar Media Inc. StockEarnings, Inc. has received a fixed fee of $25000 from Market Jar Media Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between August 14, 2025 and August 21, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Liminatus Pharma Inc (NASDAQ:LIMN) or Market Jar Media Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Liminatus Pharma Inc (NASDAQ:LIMN) on TradingWhisperer website for additional information about the relationship between Market Jar Media Inc and Liminatus Pharma Inc (NASDAQ:LIMN).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
